Drug Trial Radar · NCT03131141
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
Last checked: Nov 19, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jan 8, 2017
Primary completion
Oct 9, 2017
Study completion Mar 30, 2018
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- Collaborators
- Quotient Clinical
- First posted
- Apr 27, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 30 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-centre, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled BC-3781 administered via the intravenous or oral routes.
Conditions
- Healthy
Interventions
BC-3781Drug
Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Primary outcomes
What the sponsor says the trial is designed to measure.
- Amount of radioactivity eliminated in urineTime frame: Day 1 pre-dose to Day 8 post-dose
- Amount of radioactivity eliminated in fecesTime frame: Day 1 pre-dose to Day 8 post-dose
- Amount of radioactivity eliminated in urine and fecesTime frame: Day 1 pre-dose to Day 8 post-dose
- Cumulative amount of radioactivity eliminated in urineTime frame: Day 1 pre-dose to Day 8 post-dose
- Cumulative amount of radioactivity eliminated in fecesTime frame: Day 1 pre-dose to Day 8 post-dose
- Cumulative amount of radioactivity eliminated in urine and fecesTime frame: Day 1 pre-dose to Day 8 post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Clinical
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.